38 CFR Part 4 — 38 CFR § 4.119
Hypothyroidism — VA Diagnostic Code 7903
Endocrine
Diagnostic code
7903
38 CFR § 4.119 places Diagnostic Code 7903 in the schedule of ratings for the endocrine system. The title is “Hypothyroidism.” Two levels are printed: 100 for hypothyroidism manifesting as myxedema, and 30 for hypothyroidism without myxedema. A Note limits each evaluation in time. After that period, the Notes say to rate the residuals under the body system affected.
Reviewed 2026-10-05. Text checked against the eCFR versioner full-text XML for 2026-10-01 on 2026-10-05. Title 38 was up to date as of 2026-10-01 and last amended on 2026-08-27. The versioner lists § 4.119’s latest substantive amendment date as 2018-03-05.
The rating criteria at each level
Hypothyroidism
Rating %: 100
Criteria (verbatim). Hypothyroidism manifesting as myxedema (cold intolerance, muscular weakness, cardiovascular involvement (including, but not limited to hypotension, bradycardia, and pericardial effusion), and mental disturbance (including, but not limited to dementia, slowing of thought and depression))
Rating %: 30
Criteria (verbatim). Hypothyroidism without myxedema
| Rating % | Criteria (verbatim) |
|---|---|
| 100 | Hypothyroidism manifesting as myxedema (cold intolerance, muscular weakness, cardiovascular involvement (including, but not limited to hypotension, bradycardia, and pericardial effusion), and mental disturbance (including, but not limited to dementia, slowing of thought and depression)) |
| 30 | Hypothyroidism without myxedema |
Note (1): This evaluation shall continue for six months beyond the date that an examining physician has determined crisis stabilization. Thereafter, the residual effects of hypothyroidism shall be rated under the appropriate diagnostic code(s) within the appropriate body system(s) (e.g., eye, digestive, and mental disorders).
Note (2): This evaluation shall continue for six months after initial diagnosis. Thereafter, rate residuals of disease or medical treatment under the most appropriate diagnostic code(s) under the appropriate body system (e.g., eye, digestive, mental disorders).
Note (3): If eye involvement, such as exophthalmos, corneal ulcer, blurred vision, or diplopia, is also present due to thyroid disease, also separately evaluate under the appropriate diagnostic code(s) in § 4.79, Schedule of Ratings—Eye (such as diplopia (DC 6090) or impairment of central visual acuity (DCs 6061-6066)).
DC 7903 does not print a 0 percent line, and it does not print a percentage for the time after the periods in Notes (1) and (2). 38 CFR § 4.31 (Zero percent evaluations) says: “In every instance where the schedule does not provide a zero percent evaluation for a diagnostic code, a zero percent evaluation shall be assigned when the requirements for a compensable evaluation are not met.” Our reading: after the six-month period, the evaluation comes from the residuals the Notes name, and § 4.31 is the general rule when no compensable residual is shown. That sentence is our reading of how § 4.31 sits beside these Notes. Ask an accredited representative how VA applied it on a particular decision.
Source: 38 CFR § 4.119 (Schedule of ratings—endocrine system), Diagnostic Code 7903, eCFR full-text XML for 2026-10-01, read 2026-10-05. The titles list that day showed Title 38 up to date as of 2026-10-01 and last amended on 2026-08-27. The versioner lists § 4.119’s latest substantive amendment date as 2018-03-05. The section source note prints 61 FR 20446, May 7, 1996, as amended at 82 FR 50804, Nov. 2, 2017.
What the words mean in your records
Myxedema
The 100 percent line is “Hypothyroidism manifesting as myxedema,” followed by the features in parentheses: cold intolerance, muscular weakness, cardiovascular involvement (including, but not limited to hypotension, bradycardia, and pericardial effusion), and mental disturbance (including, but not limited to dementia, slowing of thought and depression). That sentence in § 4.119 is the rating text. The public Thyroid and Parathyroid form adds its own note: “For VA purposes, myxedema, often referred to as myxedema coma or myxedema crisis, is defined as a rare, life-threatening condition from severe hypothyroidism which requires hospitalization for stabilization and may affect several body systems.” That definition is on the form. It is not the sentence in § 4.119.
Crisis stabilization
Note (1) runs the 100 percent evaluation for six months beyond “the date that an examining physician has determined crisis stabilization.” The schedule does not add a further definition of that date. The public form asks, when myxedema has stabilized, for “the date of stabilization as determined by the examining physician.”
Initial diagnosis
Note (2) runs the 30 percent evaluation for six months after “initial diagnosis.” The schedule does not define that date. 38 CFR § 4.6 requires each element affecting the evidence to be studied so that decisions will be equitable and just. 38 CFR § 4.7 assigns the higher evaluation when the disability picture more nearly approximates the criteria required for that rating. Otherwise, the lower rating will be assigned. Our reading: the date is the first documented diagnosis. That date is our reading, not a definition printed in § 4.119.
Residuals
Note (1) says that after its six months, “the residual effects of hypothyroidism shall be rated under the appropriate diagnostic code(s) within the appropriate body system(s) (e.g., eye, digestive, and mental disorders).” Note (2) says to “rate residuals of disease or medical treatment under the most appropriate diagnostic code(s) under the appropriate body system (e.g., eye, digestive, mental disorders).” The examples printed in the Notes are eye, digestive, and mental disorders. This page does not add residual conditions the Notes do not name.
Medication
DC 7903 prints no medication criterion on the 100 or 30 line. Note (2) does say that, after the six months, the residuals rated are “residuals of disease or medical treatment.” This page does not add a rule about how treatment changes the 100 or 30 line.
Evidence that speaks to each level
30 — without myxedema
What the rater needs to see. “Hypothyroidism without myxedema,” and the initial-diagnosis date that starts the six months in Note (2).
Where that usually lives. Endocrinology or primary-care notes, and the lab reports that established the diagnosis. This page does not print a lab threshold. The schedule does not print one.
100 — myxedema
What the rater needs to see. Hypothyroidism manifesting as myxedema, with the features named in the 100 percent line, and the date an examining physician determined crisis stabilization.
Where that usually lives. Hospital records and the examining physician’s stabilization note. The form’s myxedema note, quoted above, is the form’s definition, not a substitute for the 100 percent line.
After the six-month period
What the rater needs to see. The residual effects of hypothyroidism, or residuals of disease or medical treatment, under the diagnostic codes of the body system affected. The Notes’ examples are eye, digestive, and mental disorders.
Where that usually lives. The record for each affected system the Notes name, such as an eye exam, digestive notes, or mental-health notes. The public form’s section 3E asks which body systems are affected, and section 3C tells the examiner to evaluate residuals with the questionnaires for those systems.
Eye involvement
What the rater needs to see. Eye findings “due to thyroid disease,” the examples in Note (3) being exophthalmos, corneal ulcer, blurred vision, or diplopia. Note (3) says to separately evaluate them under § 4.79.
Where that usually lives. Ophthalmology records. The eye schedule is a different section from DC 7903.
A person’s own account of symptoms, dates, and what changed can help place the diagnosis date and the residuals. The 100 and 30 lines rest on a clinician’s diagnosis and findings. This page does not print lab cutoffs.
The exam form
VA’s public DBQ list, checked October 5, 2026, names “Thyroid and Parathyroid” under Endocrinological. A separate form, “Endocrine (Other than Thyroid, Parathyroid or Diabetes Mellitus),” is listed beside it. Thyroid and Parathyroid is not on the list of questionnaires that page says are not available for public use. The page says to have a health care provider fill out the public forms. The form file is Thyroid and Parathyroid. The form header reads “Thyroid and Parathyroid Conditions,” and the copy checked that day is marked updated on April 15, 2025. This site does not yet have a thyroid DBQ guide. The index is DBQ guides.
The sections the DC 7903 lines turn on are Section 1, diagnosis, Section 3, thyroid findings, signs, and symptoms, and Section 9, diagnostic testing. Section 3C covers hypothyroid findings, the myxedema questions, and the stabilization date. It tells the examiner to evaluate current residuals with the questionnaires for the body systems identified in section 3E. That instruction matches Notes (1) and (2). Section 3E lists body systems on the form. The regulation’s examples remain the ones printed in the Notes: eye, digestive, and mental disorders.
An exam discussion is in the C&P exam guide.
Related codes and how they interact
Other thyroid codes in § 4.119
DC 7900 is “Hyperthyroidism, including, but not limited to, Graves' disease.” It prints “For six months after initial diagnosis,” 30, and then: “Thereafter, rate residuals of disease or complications of medical treatment within the appropriate diagnostic code(s) within the appropriate body system.”
DC 7906 is thyroiditis. Its note says: “Manifesting as hyperthyroidism, evaluate as hyperthyroidism, including, but not limited to, Graves' disease (DC 7900); manifesting as hypothyroidism, evaluate as hypothyroidism (DC 7903).”
DC 7919 is “C-cell hyperplasia of the thyroid.” It says: “If antineoplastic therapy is required, evaluate as a malignant neoplasm under DC 7914. If a prophylactic thyroidectomy is performed (based upon genetic testing) and antineoplastic therapy is not required, evaluate as hypothyroidism under DC 7903.” DC 7914 is “Neoplasm, malignant, any specified part of the endocrine system,” rated 100, with a note on the six months after treatment stops.
DC 7901 is thyroid enlargement, toxic. DC 7902 is thyroid enlargement, nontoxic. DC 7904 is hyperparathyroidism. DC 7905 is hypoparathyroidism. Diabetes mellitus is DC 7913. Its public page is the diabetes guide.
Residual systems
Note (3) names diplopia, DC 6090, as one example of a separate eye evaluation under § 4.79. The catalog page is DC 6090. The same note also names impairment of central visual acuity, DCs 6061-6066. Other eye codes are on the eye diagnostic-code index.
For the digestive and mental examples in Notes (1) and (2), the indexes are the digestive diagnostic-code index and the mental-health diagnostic-code index. The endocrine index is the endocrine diagnostic-code index, and the category page is endocrine conditions.
Combining
Note (3) says eye involvement due to thyroid disease is also separately evaluated under § 4.79. Notes (1) and (2) send residuals to the body system affected. 38 CFR § 4.14 says the evaluation of the same manifestation under different diagnoses is to be avoided. 38 CFR § 4.25 is the combined-ratings table. See combined VA disability rating.
Secondary conditions and presumptions
38 CFR § 3.309(a) lists “Endocrinopathies” among the chronic diseases. The chronic-disease time limit is in 38 CFR § 3.307(a)(3): the disease must have become manifest to a degree of 10 percent or more within 1 year (for Hansen's disease (leprosy) and tuberculosis, within 3 years; multiple sclerosis, within 7 years) from the date of separation from service. Section 3.309(a) does not name hypothyroidism. Whether a given diagnosis is an endocrinopathy is not stated in that section. That question is one to take to an accredited representative.
38 CFR § 3.310(d)(1)(v) says that, in a veteran with a service-connected traumatic brain injury, “Diseases of hormone deficiency that result from hypothalamo-pituitary changes if manifest within 12 months of moderate or severe TBI” shall be held to be the proximate result of that TBI, in the absence of clear evidence to the contrary. The paragraph does not name hypothyroidism. Whether a particular case fits those words is a medical question.
Any other secondary question is a medical question on the facts under § 3.310(a) and (b). Paragraph (a) covers disability proximately due to or the result of a service-connected disease or injury. Paragraph (b) covers aggravation and requires a medical baseline. See secondary aggravation and the baseline.
Short answers
What is the VA rating for hypothyroidism under DC 7903?
Under 38 CFR § 4.119, DC 7903 prints two levels: 100 for hypothyroidism manifesting as myxedema, and 30 for hypothyroidism without myxedema. Note (2) says the 30 continues for six months after initial diagnosis. Note (1) says the 100 continues for six months beyond the date an examining physician determined crisis stabilization. Afterward, the Notes say to rate the residuals under the codes for the body systems affected. Education only. VA decides on the evidence.
What does “rate residuals” mean for hypothyroidism?
The Notes under DC 7903 say that after the six-month period, the residual effects of hypothyroidism, or residuals of disease or medical treatment, are rated under the appropriate diagnostic code or codes in the body system affected. They give eye, digestive, and mental disorders as examples. Eye involvement due to thyroid disease is separately evaluated under § 4.79, Note (3).
FAQ
How does VA rate hypothyroidism under DC 7903?
Under 38 CFR § 4.119, DC 7903 prints two levels. Hypothyroidism manifesting as myxedema, with the features listed in that line, is 100. Hypothyroidism without myxedema is 30. Note (1) continues the 100 for six months beyond the date an examining physician determined crisis stabilization. Note (2) continues the 30 for six months after initial diagnosis. Afterward, the Notes say to rate the residuals under the body system affected. Education only.
How long does the 30 percent evaluation last?
Note (2) says the 30 percent evaluation shall continue for six months after initial diagnosis. Thereafter, rate residuals of disease or medical treatment under the most appropriate diagnostic code or codes under the appropriate body system. The schedule’s examples are eye, digestive, and mental disorders. The schedule does not define the words “initial diagnosis.”
What is myxedema for this code?
The 100 percent line says “Hypothyroidism manifesting as myxedema” and then lists cold intolerance, muscular weakness, cardiovascular involvement, and mental disturbance, with the examples printed in that line. The public Thyroid and Parathyroid form defines myxedema, for VA purposes, as a rare, life-threatening condition from severe hypothyroidism which requires hospitalization for stabilization and may affect several body systems. The controlling rating text is the line in § 4.119.
What does it mean to rate residuals?
Notes (1) and (2) say that after the six-month period, residual effects of hypothyroidism, or residuals of disease or medical treatment, are rated under the appropriate diagnostic code or codes in the body system affected. The Notes give eye, digestive, and mental disorders as examples. Note (3) says eye involvement due to thyroid disease is also separately evaluated under § 4.79.
What is the maximum under DC 7903?
The highest line printed under DC 7903 is 100, for hypothyroidism manifesting as myxedema. Note (1) continues that evaluation for six months beyond the date an examining physician determined crisis stabilization. The code does not print a percentage above 100, and it does not print a percentage of its own for the time after that period.
Next steps
- Read the rating decision and the exam report for DC 7903, the diagnosis date, any crisis-stabilization date, and any language that says to rate residuals.
- Gather the records for each body system the decision or the Notes point to, including eye findings due to thyroid disease when those are in the file.
- The free worksheet is a place to write the code, the measurements, and the records you already have. It does not file a claim or protect a filing date. C&P prep (Founding Pass) is a separate worksheet. An accredited representative is at find a VSO. Other endocrine codes are on the endocrine diagnostic-code index. The category page is endocrine conditions. The catalog home is the diagnostic code index.
Education only. Not legal or medical advice. My Claim Packet is not a VA-accredited representative and does not file claims. VA decides every claim on its own evidence.
Other codes in this body system
Nearby catalog entries in Endocrine, ordered by diagnostic code number. All Endocrine codes
- DC 7900Hyperthyroidism, including, but not limited to, Graves' disease
- DC 7901Thyroid enlargement, toxic
- DC 7902Thyroid enlargement, nontoxic
- DC 7904Hyperparathyroidism
- DC 7905Hypoparathyroidism
- DC 7906Thyroiditis
- DC 7907Cushing's syndrome
- DC 7908Acromegaly
- DC 7909Diabetes insipidus
- DC 7911Addison's disease (adrenocortical insufficiency)
- DC 7912Polyglandular syndrome (multiple endocrine neoplasia, autoimmune polyglandular syndrome)
- DC 7913Diabetes mellitus
- DC 7914Malignant neoplasm
- DC 7915Benign neoplasm
- DC 7916Hyperpituitarism
- DC 7917Hyperaldosteronism
Also: DC code lookup (tools) lists the same index in a compact layout.
Source: 38 CFR Part 4, Diagnostic Code 7903 • va.gov
⚠️ Important Disclaimer
This page provides general educational information based on public VA regulations and VA.gov resources. It is not legal or medical advice, and My Claim Packet is not a VA-accredited representative. Any worksheets or draft documents produced by the tools must be reviewed for accuracy and are not filed with VA for you. Ratings and service connection are decided case-by-case from the individual record. Consult a VA-accredited VSO, claims agent, attorney, or qualified clinician for help with your situation, and verify current rules using the linked official source.

